Antibody-mediated Immunogenicity against SARS-CoV-2 following priming, boosting and hybrid immunity: insights from 11 months of follow-up of a healthcare worker cohort in Israel, December 2020-October 2021

Michael Edelstein; Karine Wiegler Beiruti; Hila Ben-Amram; Naor Bar-Zeev; Christian Sussan; Hani Asulin; David Strauss; Younes Bathish; Salman Zarka; Kamal Abu Jabal

doi:10.1101/2021.12.15.21267793

Article Information

doi

https://doi.org/10.1101/2021.12.15.21267793

History

December 15, 2021.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

Michael Edelstein1,2,*,
Karine Wiegler Beiruti1,
Hila Ben-Amram1,
Naor Bar-Zeev3,
Christian Sussan1,
Hani Asulin1,
David Strauss2,
Younes Bathish1,2,
Salman Zarka1,2 and
Kamal Abu Jabal1,2,†

¹Ziv Medical Centre, Safed, Israel
²Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
³International Vaccine Access Center, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA

↵*Correspondence to: Prof. Michael Edelstein, Research Institute, Ziv Medical Centre, Safed, Israel. email: Michael.edelstein{at}biu.ac.il
↵†Alternate corresponding author: Dr Kamal Abu Jabal, Internal medicine department, Ziv medical Centre, Safed, Israel. Email: kamala{at}ziv.gov.il